- 专利标题： STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
-
申请号： US17785279申请日： 2020-12-18
-
公开(公告)号： US20230285514A1公开(公告)日： 2023-09-14
- 发明人: Elisabetta Bianchi , Paul E. Carrington , Qiaolin Deng , Songnian Lin , Federica Orvieto , Anandan Palani , Antonello Pessi , Tomi K. Sawyer
- 申请人： Elisabetta BIANCHI , Paul E. CARRINGTON , Qiaolin DENG , Songnian LIN , Federica ORVIETO , Anandan PALANI , Antonello PESSI , Tomi K. SAWYER , Merck Sharp & Dohme LLC
- 申请人地址： IT CA Pomezia (RM)
- 专利权人： Merck Sharp & Dohme LLC
- 当前专利权人： Merck Sharp & Dohme LLC
- 当前专利权人地址： US NJ Rahway
- 优先权： EP 425096.5 2019.12.23
- 国际申请： PCT/US2020/065791 2020.12.18
- 进入国家日期： 2022-06-14
- 主分类号： A61K38/26
- IPC分类号： A61K38/26 ; A61K38/28 ; C07K14/605
摘要：
The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
信息查询
IPC分类:
